Skip to main content

Cetyl Myristoleate

Uses

Cetyl myristoleate (CMO) is the common name for cis-9-cetyl myristoleate. CMO was discovered in 1972 by Harry W. Diehl, Ph.D., a researcher at the National Institutes of Health. At the time, Dr. Diehl was responsible for testing anti-inflammatory drugs on lab animals. In order for him to test the drugs, he first had to artificially induce arthritis in the animals by injecting a heat-killed bacterium called Freund’s adjuvant. Dr. Diehl discovered that Swiss albino mice did not get arthritis after injection of Freund’s adjuvant. Eventually, he was able to determine that cetyl myristoleate was the factor present naturally in mice that was responsible for this protection. When CMO was injected into various strains of rats, it offered the same protection against arthritis.1

What Are Star Ratings?

This supplement has been used in connection with the following health conditions:

Used for Why
2 Stars
Osteoarthritis
540 mg per day by mouth for 30 days
Cetyl myristoleate appears to be effective as a joint “lubricant” and anti-inflammatory agent.

(CMO) has been proposed to act as a joint “lubricant” and anti-inflammatory agent. In a double-blind trial, people with various types of arthritis who had failed to respond to nonsteroidal anti-inflammatory drugs (NSAIDs) received CMO (540 mg per day orally for 30 days), while others received a placebo. These people also applied CMO or placebo topically, according to their perceived need. A statistically significant 63.5% of those using CMO improved, compared with only 14.5% of those using placebo.

2 Stars
Rheumatoid Arthritis
540 mg daily for 30 days
Cetyl myristoleate may help relieve rheumatoid arthritis symptoms by acting as a joint “lubricant” and anti-inflammatory agent.

(CMO) has been proposed to act as a joint “lubricant” and anti-inflammatory agent. In a double-blind trial, people with various types of arthritis that had failed to respond to nonsteroidal anti-inflammatory drugs received either CMO (540 mg per day orally for 30 days) or a placebo. These people also applied CMO or placebo topically, according to their perceived need. Sixty-four percent of those receiving CMO improved, compared with 14% of those receiving placebo. More research is needed to determine whether CMO has a legitimate place in the treatment options offered RA patients.

Next Section:

How It Works
 

PeaceHealth endeavors to provide comprehensive health care information, however some topics in this database describe services and procedures not offered by our providers or within our facilities because they do not comply with, nor are they condoned by, the ethics policies of our organization.